TCT 2017: Abbott’s Xience coronary stent helps patients feel better faster than open-heart surgery

This article was originally published here

Abbott logoAbbott (NYSE:ABT) reported today that patients who were treated with the company’s Xience coronary stent for left-main coronary artery disease felt better faster compared to patients who had open-heart surgery.

The data were presented at this year’s Transcatheter Cardiovascular Therapeutics meeting during a late-breaking session.

“For any treatment, it’s important to not only consider clinical outcomes such as recurrent heart attacks or stroke, but also to consider the effect of the treatment on a patient’s quality of life,” study investigator Dr. Suzanne Baron said in prepared remarks.

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply